Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of autologous CD30-targeted CAR-T cells in relapsed/refractory classical Hodgkin lymphoma
CTR20233689Phase 2Active
- Sponsor
- Wuhan Porida Biotechnology
- Start
- May 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of BRD-01 in classical Hodgkin lymphoma (cHL), sponsored by Wuhan Porida Biotechnology. Started May 2024; status: active.
02
Drugs
BRD-01
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on CTR20233689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233689.